What happens when you stop
Most people regain a substantial share of the weight. Here is what the research actually found, and what that means for how you plan and budget.
Updated 2026-09-18
The published evidence on cessation is more consistent than most things in this field, and it is worth reading before starting rather than after.
The honest answer is that most people regain a substantial share of what they lost. A 2026 analysis published in PMC modelled the trajectory and identified a regain curve in which roughly 60% of the weight lost during treatment is regained within a year of stopping. Harvard Health, AARP and several academic medical centres have published similar guidance through 2026.
What the cessation data shows
A 2026 analysis published in PMC modelled the trajectory and identified a regain curve in which roughly 60% of the weight lost during treatment returns within a year of stopping. The mechanism is not mysterious: these drugs act on appetite signalling, and withdrawing them returns that signalling toward baseline.
Why it happens
These drugs work by changing appetite signalling — that is the whole mechanism. Stop the drug and the signalling returns to roughly where it was, including what many people describe as "food noise" coming back. It is not a failure of willpower; it is the medication no longer doing the thing it was doing.
What that means in practice
- Treat it as ongoing, not a course. Clinicians increasingly describe GLP-1 treatment the way they describe blood-pressure medication: something you may stay on, rather than a twelve-week fix.
- Budget accordingly. If this is a multi-year commitment, the difference between a $99 and a $399 programme compounds enormously. Our twelve-month cost guide sets out the arithmetic.
- Build the habits while the medication is helping. Every source we read makes the same point: the people who hold onto more of the loss are the ones who used the appetite reduction to change what they eat and how much they move, rather than waiting.
- Protein and resistance training matter more than most people are told. That is doubly true over 50 — see GLP-1s after 50.
- Ask about a maintenance dose. Stepping down rather than stopping outright is a conversation worth having with your prescriber.
Important. Why this belongs on a price comparison site. Because if treatment is likely to be long-term, the monthly number matters far more than it appears to at sign-up. A $300 difference a month is $3,600 a year and $18,000 over five. That is the real cost of not comparing properly.
Read the research in plain English
Explore how study populations, event definitions and counting rules shape a reported result.
- Semaglutide evidence in plain English: reading a severe-event percentage
A guide to the units, classifications and observation rules behind a study result, with a sourced figure and a practical framework for reading it.
- Tirzepatide study terms: how to read a decision to stop
A plain-language guide to denominators, overlapping outcomes and missing observations in a study table.
Read next
- GLP-1s after 50
These drugs work at any age. The risks are not identical at every age, and the muscle and bone question deserves more attention than it usually gets.
- The twelve-month cost
Month one is the cheapest month you will have. Here is the full-year arithmetic, including the costs nobody puts in the advert.
- Medicare, GLP-1s and the $50 month
CMS is running a time-limited programme giving eligible Part D members certain GLP-1s for $50 a month. If you are on Medicare, read this before paying cash for anything.
- Reading your label
What each line on the vial and the paperwork means, and the four things to check the moment the box arrives.
- Who should not take these
The contraindications and interactions an online questionnaire may not catch. Worth reading before you fill one in.
Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure